Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
List view / Grid view
Alzheimer's disease (AD)
Filter the results
New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
Scientists have produced the first pathoconnectome - an open access map for other researchers that shows how eye disease can alter retinal circuitry.
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
The team found that the expression of the APOE4 gene variant in pericytes caused amyloid plaque formation in a blood-brain barrier model.